Docket No. JJM5023USPCT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Breda Mary Cullen et al.

For : WOUND DRESSINGS FOR THE CONTROLLED RELEASE OF

THERAPEUTIC AGENTS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth

in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with [ ] the first or ☐second After Final Submission, therefore: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10-/ the fee of \$180.00 as set forth §1.17(p). in In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

	Copi	es of each of the references listed on the
attached	Form 1	PTO-1449 are enclosed herewith.
	Copi	es of references listed on the attached Form PTO-
1449 are	enclo	sed herewith EXCEPT THAT:
		In view of the voluminous nature of references
		[list as appropriate], and the likelihood that
		these references are available to the Examiner,
		copies are not enclosed herewith.
		If any of the foregoing publications are not
		available to the Examiner, Applicant will
		endeavor to supply copies at the Examiner's
•		request.
•		
$\boxtimes$	Copi	es of only foreign patent documents and non-
patent li		are are enclosed in accordance with 37 CFR 1.98
(a)(2).		
$\bowtie$	There	e are no listed references, which are not in the
English 1		
	5	,
П	The :	relevance of those listed references which are
not in th		lish language is as follows:
	· 5 ·	
П	Atta	ched are copies of search report(s) from
correspon		patent application(s), which are listed on the
		ssion Under MPEP 609 D.
	_ <b></b>	
	Atta	ched are the following non-published pending
പ patent an		cions which may be deemed relevant, which are
		attached Submission Under MDED 609 D

· · >

.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JJM5023USPCT/BEL. This form is submitted in triplicate.

Respectfully submitted,

/Blossom E. Loo/

Blossom E. Loo Reg. No. 36,858 Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-1596 DATED: May 19, 2006

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

the control hamber.						
Application Number	1220007					
Filing Date	W 31 1 471					
First Named Inventor	Breda Mary Cullen					
Group Art Unit						
Examiner Name						
Attorney Docket Number	JJM5023USPCT					

U.S. PATENT DOCUMENTS									
Examiner Initials	Cite	U.S. Patent Docume	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear			
		5770229	Α	Tanihara et al.	06/23/1998				
		2002/012693	A1	Cohen et al.	01/31/2002				
	ļ								

## FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication Pages, Columns, Lines, of Cited Document Name of Patentee or where relevant Examiner Vinice<sup>3</sup> Number<sup>4</sup> KindCode<sup>5</sup> passages or relevant mm-dd-yyyy T<sup>6</sup> Applicant of Cited Document Initials figures appear No.1 2382775 GB Johnson & Johnson Medical Ltd. 06/11/2003 Х 04/096302 WO Johnson & Johnson Medical Ltd. Α 11/11/2004 Х 04/030711 WO Johnson & Johnson Medical Ltd. Α 04/15/2004 Х

Examine	r	Date	
Signatur	9	Considered	ŀ

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.